United Therapeutics Corp Dossier
Qualitative Analysis
Business overview
United Therapeutics Corporation (Nasdaq: UTHR) is a pioneering, public benefit biotechnology company dedicated to developing innovative therapies for unmet medical needs. The company's primary commercial focus is on pulmonary arterial hypertension (PAH) and other chronic, life-threatening conditions such as pulmonary fibrosis and pediatric cancer. United Therapeutics is also globally recognized for its long-term, revolutionary pursuit of solving the acute shortage of transplantable organs through advanced organ manufacturing, xenotransplantation, regenerative medicine, and 3D organ printing technologies.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Development of a proprietary drug-device formulation of treprostinil delivered via a soft mist inhaler (SMI) designed to reduce coughing by up to 90% compared to dry powder inhalers.
Expected impact: Aims to eliminate therapy discontinuation due to cough, serving as a defensive moat against competitive dry powder inhaler launches.
A Phase 1/2/3 multicenter, open-label clinical trial evaluating the safety and efficacy of the investigational UKidney, derived from a genetically modified pig, in patients with end-stage renal disease (ESRD).
Expected impact: Pioneers a solution to the severe shortage of transplantable organs, establishing a first-mover advantage in a multi-billion-dollar market.
Collaboration with 3D Systems to design and manufacture 3D-printed human lung scaffolds with 44 trillion voxels and 4,000 km of pulmonary capillaries, demonstrating gas exchange in animal models.
Expected impact: Aims to create an unlimited supply of tolerable, transplantable organs, starting with lungs and expanding to kidneys and livers.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To expand United Therapeutics' existing complementary platform of organ manufacturing programs, bringing in new approaches, highly skilled personnel, and state-of-the-art facilities to complement existing programs.
Financial impact: Includes an additional $1.75 per share in cash contingent upon achieving a clinical development milestone related to the fully implantable manufactured kidney product (mirokidney) by December 31, 2025.
Strategic Partnerships
To explore the use of microgravity in low Earth orbit to develop improved formulations of small-molecule treatments for rare pulmonary diseases, leveraging microgravity's effects on crystallization to enhance drug stability and delivery.
Terms: Terms not disclosed; announced on May 13, 2026
Expanded in August 2025 to develop a second dry powder inhalation therapy using MannKind's proprietary Technosphere platform, building on the commercial success of Tyvaso DPI.
Terms: MannKind received a $5 million upfront payment and is eligible for up to $35 million in development milestones plus 10% royalties on net sales of any resulting product.
Collaboration for the development, manufacture, and supply of the Remunity and RemunityPRO Pumps used for subcutaneous delivery of Remodulin.
Terms: United Therapeutics funds development costs and pays product fees plus a single-digit royalty to DEKA based on commercial sales.